Abstract
The success of a drug treatment is strongly correlated with the ability of a molecule to reach its target in the patient's organism without inducing toxic effects. Moreover the reduction of cost and time associated with drug discovery and development is becoming a crucial requirement for pharmaceutical industry. Therefore computational methods allowing reliable predictions of newly synthesized compounds properties are of outmost relevance. In this paper we discuss the role of genetic programming in predictive pharmacokinetics, considering the estimation of adsorption, distribution, metabolism, excretion and toxicity processes (ADMET) that a drug undergoes into the patient's organism. We compare genetic programming with other well known machine learning techniques according to their ability to predict oral bioavailability (%F), median oral lethal dose (LD50) and plasma-protein binding levels (%PPB). Since these parameters respectively characterize the percentage of initial drug dose that effectively reaches the systemic blood circulation, the harmful effects and the distribution into the organism of a drug, they are essential for the selection of potentially good molecules. Our results suggest that genetic programming is a valuable technique for predicting pharmacokinetics parameters, both from the point of view of the accuracy and of the generalization ability.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
